Results 151 to 160 of about 274,173 (312)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Progress in Thyroid Cancer Genomics: A 40-Year Journey. [PDF]

Thyroid, 2023
Fagin JA, Nikiforov YE.
europepmc   +1 more source

Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data

, 2016
Fan Zhang, Chunyan Ren, Hengqiang Zhao, Lei Yang, Fei Su, Ming‐Ming Zhou, Junwei Han, Eric A. Sobie, Martin J. Walsh   +8 more
openalex   +2 more sources

Supplemental Table 6 from The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor–Positive Metastatic Breast Cancer

, 2023
Seth A. Wander, Ofir Cohen, Xueqian Gong, Gabriela N. Johnson, Jorge E. Buendia-Buendia, Maxwell R. Lloyd, Dewey Kim, Flora Luo, Pingping Mao, Karla Helvie, Kailey J. Kowalski, Utthara Nayar, Adrienne G. Waks, Stephen H. Parsons, Ricardo Martínez, Lacey M. Litchfield, Xiang S. Ye, Chunping Yu, Valerie M. Jansen, John R. Stille, Patricia S. Smith, Gerard J. Oakley, Quincy S. Chu, Gerald Batist, Melissa E. Hughes, Jill D. Kremer, Levi A. Garraway, Eric P. Winer, Sara M. Tolaney, Nancy U. Lin, Sean G. Buchanan, Nikhil Wagle   +31 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

Editorial: Accelerating cancer genomics research in Sub-Saharan Africa. [PDF]

Front Oncol
Odedina FT, Rotimi SO, Zoure AA.
europepmc   +1 more source

Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know. [PDF]

Radiol Imaging Cancer, 2023
Mendes Serrão E, Klug M, Moloney BM, Jhaveri A, Lo Gullo R, Pinker K, Luker G, Haider MA, Shinagare AB, Liu X.   +9 more
europepmc   +1 more source

Supplementary Data S6 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors

, 2023
Naoual Menssouri, Loïc Poiraudeau, Carole Hélissey, Ludovic Bigot, Jonathan Sabio, Tony Ibrahim, Cédric Pobel, Claudio Nicotra, Maud Ngo‐Camus, Ludovic Lacroix, Étienne Rouleau, Lambros Tselikas, Anne Chauchereau, Félix Blanc‐Durand, Alice Bernard‐Tessier, Anna Patrikidou, Natacha Naoun, Ronan Flippot, Émeline Colomba, Alina Fuerea, Laurence Albigès, Pernelle Lavaud, Paul van de Wiel, Eveline den Biezen, Yvonne Wesseling-Rozendaal, Santiago Ponce, Stefan Michiels, Christophe Massard, Daniel Gautheret, Fabrice Barlési, Fabrice André, Benjamin Besse, Jean‐Yves Scoazec, Luc Friboulet, Karim Fizazi, Yohann Loriot   +35 more
openalex   +1 more source

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Artificial intelligence in cancer genomics: refining diagnosis of hereditary breast and ovarian cancer syndromes. [PDF]

Ann Med Surg (Lond)
Khizar M, Zaib M, Babar M, Karimi H, Aminpoor H.   +4 more
europepmc   +1 more source